<DOC>
	<DOCNO>NCT00389766</DOCNO>
	<brief_summary>RATIONALE : Radioisotope therapy , iodine I 131 metaiodobenzylguanidine ( MIBG ) , release radiation kill tumor cell . Drugs use chemotherapy , topotecan , work different way stop growth tumor cell , either kill cell stop dividing . Topotecan may also make tumor cell sensitive iodine I 131 MIBG . A peripheral stem cell transplant may able replace blood-forming cell destroy iodine I 131 MIBG topotecan . This may allow iodine I 131 MIBG topotecan give tumor cell kill . PURPOSE : This phase II trial study well give high-dose iodine I 131 MIBG together topotecan peripheral stem cell transplant work treat young patient relapse stage 4 neuroblastoma primary resistant high-risk neuroblastoma .</brief_summary>
	<brief_title>High-Dose Iodine I 131 Metaiodobenzylguanidine , Topotecan , Peripheral Stem Cell Transplant Treating Young Patients With Relapsed Stage 4 Neuroblastoma Primary Resistant High-Risk Neuroblastoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine response ( partial complete response metastatic site ) child relapse stage 4 neuroblastoma primary resistant high-risk neuroblastoma treat high-dose iodine I 131 metaiodobenzylguanidine , topotecan hydrochloride , peripheral blood stem cell transplantation . - Determine proportion patient , result treatment , able progress potentially curative surgery systemic treatment . - Correlate tumor dosimetry ( determine whether tumor absorb radiation dose ) response patient treat regimen . - Determine time tumor progression . OUTLINE : This open-label , multicenter study . Patients stratify accord disease type ( relapse stage 4 vs primary resistant high-risk neuroblastoma ) . Patients receive topotecan hydrochloride IV 30 minute day 1-5 15-19 high-dose iodine I 131 metaiodobenzylguanidine ( ^131I-MIBG ) IV 30 minute day 1 15 . Patients receive autologous CD 34+ peripheral blood stem cell ^131I-MIBG dosimetry level reach acceptable low day 25-29 . Total whole-body absorbed dose measure periodically first ^131I-MIBG dose administer periodically thereafter . After completion study treatment , patient follow periodically 10 year . PROJECTED ACCRUAL : A total 67 patient accrue study .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<mesh_term>Iodine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Confirmed diagnosis neuroblastoma meet 1 follow criterion : Primary resistant highrisk disease meeting follow criterion : International neuroblastoma stag system ( INSS ) stage 4 , stage 2 3 myelocytomatosis viralrelated oncogene ( MycN ) amplification Failed achieve satisfactory remission induction chemotherapy , define one following : Less 50 % reduction &gt; 3 positive site iodine I 131 metaiodobenzylguanidine ( ^131IMIBG ) scintigraphy Persistent cytomorphological positive disease bone marrow aspirate trephine biopsy Progressive disease necessitate change treatment Relapsed stage 4 disease meeting follow criterion : Highrisk neuroblastoma ( INSS stage 4 , stage 2 3 MycN amplification ) Relapsed intensive treatment include highdose chemotherapy hematopoietic progenitor cell support Patients may enter time relapse , point subsequently treatments ^131IMIBGpositive disease diagnostic scintigraphy Peripheral blood stem cell harvest ≥ 300,000/mm³ CD 34+ cell Enrolled treat protocol SIOPNB2009 similar protocol PATIENT CHARACTERISTICS : Glomerular filtration rate ≥ 50 mL/min Considered fit enough undergo propose study treatment PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>June 2007</verification_date>
	<keyword>localize unresectable neuroblastoma</keyword>
	<keyword>recurrent neuroblastoma</keyword>
	<keyword>regional neuroblastoma</keyword>
	<keyword>localize resectable neuroblastoma</keyword>
	<keyword>disseminate neuroblastoma</keyword>
</DOC>